Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026.

Evonile Pharma Limited (formerly known as Novartis India Limited) November 04, 2026 The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 500672 Subject: Audio Recording of Earnings Call held on November 4, 2026, for Unaudited Financial Results for the Quarter and Half-Year Ended September 30, 2026 Ref.: Disclosure under regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, This is with reference to our earlier intimations dated October 26, 2026, regarding the Earnings Call in relation to the unaudited financial results of Evonile Pharma Limited (formerly known as Novartis India Limited) (‘the Company’) for the quarter and half-year ended September 30, 2026 pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “SEBI Listing Regulations”). The presentation for the earnings call was also submitted with BSE on November 03, 2026. The aforesaid Call was held today i.e. Wednesday, November 04, 2026, through Virtual Mode. Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 46(2) of the SEBI Listing Regulations, we wish to inform you that the audio recording of the aforesaid Call has been uploaded on the Company’s website and is available at the following link: https://evonilepharma.com/earnings-call/ We further confirm that no unpublished price sensitive information was shared or discussed during the aforesaid call. The above disclosure is being submitted for your information and records. You are requested to take note of the same. For Evonile Pharma Limited (formerly known as Novartis India Limited) Chandni Maru Company Secretary and Compliance Officer A60291 Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com